Aerovate Therapeutics (AVTE) Stock Highlights

1.65 | -93.3%

2024-06-18 02:41:42

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.

Statistics

Range Today

1.5 2.51

Volume Today 24.69M

Range 1 Year

9.41 32.42

Volume 1 Year 29.63M

Range 3 Year

7.74 32.42

Volume 3 Year 78.62M

Range 10 Year

7.74 32.42

Volume 10 Year 78.62M

Highlights

Market Capitalization 709.61M (small)

Floating Shares 11.09M

Current Price 1.65

Price To Earnings -7.94

Price To Book 7.56

Earnings Per Share -3.03

Payout Ratio 0%

Performance

Latest -93.3%

1 Month -92.45%

3 Months -93.83%

6 Months -90.84%

1 Year -90.02%

3 Years -94.11%

5 Years -94.11%

10 Years -94.11%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.